Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenon Medical (TNON) Total Non-Current Liabilities (2021 - 2025)

Tenon Medical has reported Total Non-Current Liabilities over the past 5 years, most recently at $4.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 135.17% year-over-year to $4.7 million; the TTM value through Dec 2025 reached $4.7 million, up 135.17%, while the annual FY2025 figure was $4.7 million, 135.17% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $4.7 million at Tenon Medical, up from $4.1 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $16.2 million in Q4 2021 and troughed at $2.0 million in Q4 2024.
  • A 5-year average of $4.7 million and a median of $3.6 million in 2023 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 70.35% in 2022 and later surged 135.17% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $16.2 million in 2021, then tumbled by 70.35% to $4.8 million in 2022, then rose by 14.36% to $5.5 million in 2023, then plummeted by 63.37% to $2.0 million in 2024, then skyrocketed by 135.17% to $4.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for TNON at $4.7 million in Q4 2025, $4.1 million in Q3 2025, and $2.6 million in Q2 2025.